Viteava Pharmaceuticals Inc.

is a start-up drug development company focused on addressing significant unmet medical needs in women’s health and oncology. It is a world leader in chemistry and biology of small molecule analogs and derivatives related to the green tea flavonoid, (-) epigallocatechin-3-gallate (EGCG). A large volume of scientific literature has demonstrated the health benefits of green tea and EGCG, however the therapeutic use of EGCG is limited by its poor bioavailability. Viteava’s drug candidates affect important biological pathways targeted by EGCG, while demonstrating enhanced potency and bioavailability in the absence of significant toxicity.

Viteava’s strategy leverages clinical data with green tea extracts in patients where biological responses have been observed. The company’s drug candidates are designed to improve these treatment regimens and enhance the biological responses.

Viteava is a virtual company with R&D activities in Toronto, Detroit, and Hong Kong. It hopes to bring its first drug candidate to the clinic before the end of 2016. The company’s unique technology platform is based on a rationally-designed library of novel compounds derived from EGCG. Viteava leverages more than 12 years of research in this field from the laboratories of Professor Tak-Hang (Bill) Chan of McGill University and the Hong Kong Polytechnic University and Professor Q. Ping Dou of Wayne State University.

The company has secured an exclusive worldwide license to a portfolio of intellectual property developed at McGill University, Wayne State University, the Hong Kong Polytechnic University, the H. Lee Moffitt Cancer Center and the University of South Florida. Patents have issued in the U.S., Japan, India, and China and are under prosecution in other international jurisdictions.